RBC Capital Mkts initiated coverage on BeiGene with a new price target
$ONC
Biotechnology: Pharmaceutical Preparations
Health Care
RBC Capital Mkts initiated coverage of BeiGene with a rating of Outperform and set a new price target of $312.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/18/2025 | $385.00 | Overweight | Barclays |
| 4/7/2025 | $312.00 | Outperform | RBC Capital Mkts |
| 3/3/2025 | $207.00 → $320.00 | Neutral → Buy | BofA Securities |
4 - BeOne Medicines Ltd. (0001651308) (Issuer)
4 - BeOne Medicines Ltd. (0001651308) (Issuer)
4 - BeOne Medicines Ltd. (0001651308) (Issuer)
Study met its primary endpoint of overall response rate (ORR), demonstrating clinically meaningful responses in rare B-cell lymphoma with high unmet need BeOne to submit data to global regulatory authorities for their review and potential approval BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, today announced positive topline results from a Phase 1/2 study (BGB-11417-201) of sonrotoclax, a next-generation and potentially best-in-class investigational BCL2 inhibitor, in adult patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), following treatment with a Bruton's tyrosine kinase inhibitor (BTKi) and anti-CD20 therapy. BeOne plans t
Final analysis of RATIONALE-315 demonstrates clear overall survival benefit in perioperative setting in resectable non-small cell lung cancer Broad EU label with nine approved indications in solid tumors, including five in lung cancer, highlights TEVIMBRA's therapeutic range and strong clinical profile throughout the care continuum BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, today announced that the European Commission (EC) has approved TEVIMBRA (tislelizumab), in combination with platinum-containing chemotherapy as neoadjuvant treatment followed by TEVIMBRA monotherapy as adjuvant treatment, for adult patients with resectable non-small cell
BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, today announced it will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8, 2025, with a fireside chat at 1:50 p.m. EDT. The live webcast of this event can be accessed from the investors section of the Company's website at https://ir.beonemedicines.com, https://hkexir.beonemedicines.com, https://sseir.beonemedicines.com. An archived webcast will be available on the Company's website. About BeOne Medicines BeOne Medicines is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and
144 - BeOne Medicines Ltd. (0001651308) (Subject)
144 - BeOne Medicines Ltd. (0001651308) (Subject)
144 - BeOne Medicines Ltd. (0001651308) (Subject)
Barclays initiated coverage of BeOne Medicines with a rating of Overweight and set a new price target of $385.00
RBC Capital Mkts initiated coverage of BeiGene with a rating of Outperform and set a new price target of $312.00
BofA Securities upgraded BeiGene from Neutral to Buy and set a new price target of $320.00 from $207.00 previously
Second quarter total revenues increased 42% to $1.3 billion versus second quarter 2024 Global BRUKINSA revenues increased 49% to $950 million versus second quarter 2024 Reported diluted GAAP Earnings per American Depositary Share (ADS) of $0.84, non-GAAP diluted Earnings per ADS of $2.25 Anticipate 20+ milestones in next 18 months across hematology and solid tumor pipeline BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, today announced financial results and corporate updates from the second quarter of 2025. "Our strong second quarter performance reinforces our trajectory as a global oncology powerhouse and underscores our proven abilit
First quarter 2025 total revenues increased 49% to $1.1 billion with BRUKINSA® (zanubrutinib) global sales increasing 62% to $792 million on strong demand growth versus first quarter 2024 Achieved GAAP profitability and significantly improved operating cash flow Advanced late-stage hematology and solid tumor pipelines with plan to host Investor R&D Day on June 26 Secured shareholder approval to rename the Company to BeOne Medicines Ltd. and redomicile to Switzerland BeiGene, Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company that will change its name to BeOne Medicines, Ltd., today announced financial results and corporate updates from the first quarter 2025.
BeiGene, Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company that intends to change its name to BeOne Medicines Ltd., will report its first quarter 2025 financial results on Wednesday, May 7, 2025 before the financial markets open. Following the release of the financials, the Company will host a live webcast with management at 8:00 a.m. ET. The conference call will be webcast live and a link to the webcast can be accessed from the investors section of the Company's website at http://ir.beigene.com/, https://hkexir.beigene.com/, https://sseir.beigene.com/. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the schedul